Selicrelumab
Based on 1 Customer Validation
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.29%
- CAS No.: 1622140-49-1
- 분자량:146.2 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG2 kappa
Human
CD40
Selicrelumab (10 µg/mL, 2-3 days) activates the CD40 receptor on chronic lymphocytic leukemia (CLL) cells, upregulates co-stimulatory molecules (CD86), cytokines (TNF-α) and death receptors (CD95) in primary CLL cells[2].
Selicrelumab (10 µg/mL, 2 days) promotes the expression of anti-apoptotic protein MCL-1, induces resistance to Venetoclax (HY-15531) in CLL cells[2].
Selicrelumab (10 µg/mL, 2 days) enhances the sensitivity of CLL cells to GA101 (HY-P9910)-induced cell death through a lysosome-mediated mechanism[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:primary CLL cell
-
Concentration:10 µg/mL
-
Incubation Time:2 days
-
Result:Upregulated the expression of Mcl-1.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
P25942-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD40 (red) with Selicrelumab (anti-CD40) (HY-P99046). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody. -
Immobilized CD40 Protein, Human can bind Selicrelumab. The EC50 for this effect is 22.34 ng/mL.
Chemical Information
-
CAS No. 1622140-49-1
-
Appearance Liquid
-
분자량 146.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Selicrelumab]
-
Synonyms
CP-870893; RG-7876
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Katelyn T Byrne, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. [Content Brief]
[2]. Delgado R, et al., Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers (Basel). 2021 Jun 21;13(12):3084. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)